An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

INTRODUCTION: Patients with advanced, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC) with Exon 20 insertion mutations (Exon20ins) have poor prognoses, exacerbated by a previous lack of specific treatment guidelines and unmet need for targeted therapies. Amivantam...

Descripción completa

Detalles Bibliográficos
Autores principales: Chouaid, Christos, Bosquet, Lise, Girard, Nicolas, Kron, Anna, Scheffler, Matthias, Griesinger, Frank, Sebastian, Martin, Trigo, Jose, Viteri, Santiago, Knott, Craig, Rodrigues, Bernardo, Rahhali, Nora, Cabrieto, Jedelyn, Diels, Joris, Perualila, Nolen J., Schioppa, Claudio A., Sermon, Jan, Toueg, Raphael, Erdmann, Nicole, Mielke, Janka, Nematian-Samani, Mehregan, Martin-Fernandez, Cristina, Pfaira, Innocent, Li, Tracy, Mahadevia, Parthiv, Wolf, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988783/
https://www.ncbi.nlm.nih.gov/pubmed/36652175
http://dx.doi.org/10.1007/s12325-022-02408-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988783/
https://www.ncbi.nlm.nih.gov/pubmed/36652175
http://dx.doi.org/10.1007/s12325-022-02408-7

Ejemplares similares